dexborneol/cilostazol (Y-6 sublingual)
/ NeuroDawn
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 07, 2025
Phase III Clinical Trial of Y-6 Sublingual Tablets for the Treatment of Acute Ischemic Stroke - A Multicenter, Randomized, Double-Blind, Placebo-Parallel Controlled Trial
(ChiCTR)
- P3 | N=892 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital Affiliated to Capital Medical University; NeuroDawn Pharmaceutical Co., Ltd.
New P3 trial • Cardiovascular • Ischemic stroke
June 27, 2025
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
(clinicaltrials.gov)
- P3 | N=892 | Not yet recruiting | Sponsor: Beijing Tiantan Hospital
New P3 trial • Cardiovascular • Ischemic stroke
1 to 2
Of
2
Go to page
1